Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)

NCT05741294 is registered in ClinicalTrials.gov with Almirall, S.A. as lead sponsor.

NCT NCT05741294
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05741294 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open Phase IV Study to Assess the Impact of Tirbanibulin on the Wellbeing of Patients With Actinic Keratoses (TIRBASKIN)
Lead sponsor
Almirall, S.A.
Phase
Phase 4
Overall status
Completed
Start date
January 20, 2023
Completion date
January 19, 2024
Enrollment
334 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

actinic keratosis